Exam 1: Introduction to Mergers, acquisitions, and Other Restructuring Activities

Joe's barber shop buys Jose's Hair Salon.Which of the following terms best describes this deal?

Financial restructuring generally refers to actions taken by the firm to change total debt and equity structure.

A horizontal merger occurs between two companies within the same industry.

Which of the following is not true of unrelated diversification?

The purpose of a "fairness" opinion from an investment bank is

Holding companies can gain effective control of other companies by owning significantly less than 100% of their outstanding voting stock.

Institutional investors in private companies often have considerable influence approving or disapproving proposed mergers.Which of the following are generally not considered institutional investors?

When investment bankers are paid by a firm's board to evaluate a proposed takeover bid,their opinions are given in a so-called "fairness letter."

In a statutory merger,the acquiring company assumes the assets and liabilities of the target firm in accordance with the prevailing federal government statutes.

Restaurant chain,Camin Holdings,acquired all of the assets and liabilities of Cheesecakes R Us.The combined firm is known as Camin Holdings and Cheesecakes R Us no longer exists as a separate entity.The Acquisition is best described as a:

Operational restructuring refers to the outright or partial sale of companies or product lines or to downsizing by closing unprofitable or non-strategic facilities.

The target company is the firm being solicited by the acquiring company.

Which of the following are often participants in the acquisition process?

A steel maker acquired a coal mining company.Which of the following terms best describes this deal?

Post-merger returns to shareholders often do not meet expectations.However,this is also true of such alternatives to M&As as joint ventures,alliances,and new product introductions.

ESOPs may be used for which of the following?

Most empirical studies support the conclusion that unrelated diversification benefits a firm's shareholders.

Joint ventures are cooperative business relationships formed by two or more separate parties to achieve common strategic objectives

Pfizer Acquires Pharmacia to Solidify Its Top Position In 1990, the European and U.S. markets were about the same size; by 2000, the U.S. market had grown to twice that of the European market. This rapid growth in the U.S. market propelled American companies to ever increasing market share positions. In particular, Pfizer moved from 14th in terms of market share in 1990 to the top spot in 2000. With the acquisition of Pharmacia in 2002, Pfizer's global market share increased by three percentage points to 11%. The top ten drug firms controlled more than 50 percent of the global market, up from 22 percent in 1990. Pfizer is betting that size is what matters in the new millennium. As the market leader, Pfizer was finding it increasingly difficult to sustain the double-digit earnings growth demanded by investors. Such growth meant the firm needed to grow revenue by $3-$5 billion annually while maintaining or improving profit margins. This became more difficult due to the skyrocketing costs of developing and commercializing new drugs. Expiring patents on a number of so-called blockbuster drugs (i.e., those with potential annual sales of more than $1 billion) intensified pressure to bring new drugs to market. Pfizer and Pharmacia knew each other well. They had been in a partnership since 1998 to market the world's leading arthritis medicine and the 7th largest selling drug globally in terms of annual sales in Celebrex. The companies were continuing the partnership with 2nd generation drugs such as Bextra launched in the spring of 2002. For Pharmacia's management, the potential for combining with Pfizer represented a way for Pharmacia and its shareholders to participate in the biggest and fastest growing company in the industry, a firm more capable of bringing more products to market than any other. The deal offered substantial cost savings, immediate access to new products and markets, and access to a number of potentially new blockbuster drugs. Projected cost savings are $1.4 billion in 2003, $2.2 billion in 2004, and $2.5 billion in 2005 and thereafter. Moreover, Pfizer gained access to four more drug lines with annual revenue of more than $1 billion each, whose patents extend through 2010. That gives Pfizer, a portfolio, including its own, of 12 blockbuster drugs. The deal also enabled Pfizer to enter three new markets, cancer treatment, ophthalmology, and endocrinology. Pfizer expects to spend $5.3 billion on R&D in 2002. Adding Pharmacia's $2.2 billion brings combined company spending to $7.5 billion annually. With an enlarged research and development budget Pfizer hopes to discover and develop more new drugs faster than its competitors. On July 15, 2002, the two firms jointly announced they had agreed that Pfizer would exchange 1.4 shares of its stock for each outstanding share of Pharmacia stock or $45 a share based on the announcement date closing price of Pfizer stock. The total value of the transaction on the announcement was $60 billion. The offer price represented a 38% premium over Pharmacia's closing stock price of $32.59 on the announcement date. Pfizer's shareholders would own 77% of the combined firms and Pharmcia's shareholders 23%. The market punished Pfizer, sending its shares down $3.42 or 11% to $28.78 on the announcement date. Meanwhile, Pharmacia's shares climbed $6.66 or 20% to $39.25. : -Would you anticipate continued consolidation in the global pharmaceutical industry? Why or why not?

Pfizer Acquires Pharmacia to Solidify Its Top Position In 1990, the European and U.S. markets were about the same size; by 2000, the U.S. market had grown to twice that of the European market. This rapid growth in the U.S. market propelled American companies to ever increasing market share positions. In particular, Pfizer moved from 14th in terms of market share in 1990 to the top spot in 2000. With the acquisition of Pharmacia in 2002, Pfizer's global market share increased by three percentage points to 11%. The top ten drug firms controlled more than 50 percent of the global market, up from 22 percent in 1990. Pfizer is betting that size is what matters in the new millennium. As the market leader, Pfizer was finding it increasingly difficult to sustain the double-digit earnings growth demanded by investors. Such growth meant the firm needed to grow revenue by $3-$5 billion annually while maintaining or improving profit margins. This became more difficult due to the skyrocketing costs of developing and commercializing new drugs. Expiring patents on a number of so-called blockbuster drugs (i.e., those with potential annual sales of more than $1 billion) intensified pressure to bring new drugs to market. Pfizer and Pharmacia knew each other well. They had been in a partnership since 1998 to market the world's leading arthritis medicine and the 7th largest selling drug globally in terms of annual sales in Celebrex. The companies were continuing the partnership with 2nd generation drugs such as Bextra launched in the spring of 2002. For Pharmacia's management, the potential for combining with Pfizer represented a way for Pharmacia and its shareholders to participate in the biggest and fastest growing company in the industry, a firm more capable of bringing more products to market than any other. The deal offered substantial cost savings, immediate access to new products and markets, and access to a number of potentially new blockbuster drugs. Projected cost savings are $1.4 billion in 2003, $2.2 billion in 2004, and $2.5 billion in 2005 and thereafter. Moreover, Pfizer gained access to four more drug lines with annual revenue of more than $1 billion each, whose patents extend through 2010. That gives Pfizer, a portfolio, including its own, of 12 blockbuster drugs. The deal also enabled Pfizer to enter three new markets, cancer treatment, ophthalmology, and endocrinology. Pfizer expects to spend $5.3 billion on R&D in 2002. Adding Pharmacia's $2.2 billion brings combined company spending to $7.5 billion annually. With an enlarged research and development budget Pfizer hopes to discover and develop more new drugs faster than its competitors. On July 15, 2002, the two firms jointly announced they had agreed that Pfizer would exchange 1.4 shares of its stock for each outstanding share of Pharmacia stock or $45 a share based on the announcement date closing price of Pfizer stock. The total value of the transaction on the announcement was $60 billion. The offer price represented a 38% premium over Pharmacia's closing stock price of $32.59 on the announcement date. Pfizer's shareholders would own 77% of the combined firms and Pharmcia's shareholders 23%. The market punished Pfizer, sending its shares down $3.42 or 11% to $28.78 on the announcement date. Meanwhile, Pharmacia's shares climbed $6.66 or 20% to $39.25. : -In your opinion,is this transaction likely to succeed or fail to meet investor expectations? Explain your answer.